Pulmonary Function Tests

Assoc. Prof. John Smithson

Learning outcomes

Be able to:

- Be able to relate the concepts of FVC, FEV1 and FVC/FEV1 ratio to obstructive and restrictive disease.
- Understand reported spirometry results in relation to disease
- Be able to explain changes in peak flow in relation to changes in respiratory disease status

COMMONWEALTH OF AUSTRALIA

Copyright Regulations 1969

WARNING

This material has been reproduced and communicated to you by or on behalf of James Cook University in accordance with section 113P of the Copyright Act 1968 (Act).

The material in this communication may be subject to copyright under the Act. Any further reproduction or communication of this material by you may be the subject of copyright protection under the Act.

Do not remove this notice



Pulmonary Function Tests

- Pulmonary function tests provide objective data on a patients lung function.
- Used to
 - Measure underlying lung function
 - Changes in lung function secondary to treatment or exacerbations
 - Monitor changes in progressive lung disease such as COPD
 - Monitor lung function during use of drugs toxic to the lungs

- Most common pulmonary function tests used include
 - Lung volumes
 - Spirometry
 - Lung flow volume loops
 - Peak expiratory flow

Spirometry

- Performed for <u>every</u> patient with suspected asthma
- In general practice, spirometry aims to:
 - Assess variability of airflow obstruction
 - Measure the degree of airflow obstruction compared to normal
- Allows differentiation between asthma and COPD
- Allows differentiation between obstructive and restrictive disease
- Can determine if airflow limitation is reversible
- The following video from the Asthma Management Council shows how spirometry is performed (4:15 minutes).
- https://www.nationalasthma.org.au/living-with-asthma/how-tovideos/performing-spirometry-in-primary-care


Spirometry

Measures lung volume (directly) and capacity (inferred from volume)


Average lung capacity of an adult male = 6 litres

Average lung capacity of an adult female = 4.5 litres

Allows differentiation between:



Important lung volumes




• Figure 23.15

- Tidal volume
- Inspiratory reserve volume
- Forced Vital Capacity (FVC)
- Forced Expiratory Volume₁ (FEV₁)
- Ratio of FEV/FVC
- Peak flow

Images taken from Tortora, GJ., Derrickson, B., Burkett, B., Peoples, G., Dye, D., Cooke, J., et al. Principles of anatomy and physiology. Second Asia-Pacific ed. Queensland, Australia: John Wiley & Sons; 2019.

Patterns of Respiratory disease

- Obstructive disease (COPD / Asthma)
 - Decreased FEV1,
 - Normal or decreased FVC,
 - Decreased FEV1/FVC ratio (normal is 70-80%)
- Restrictive disease (Interstitial lung disease, semi-paralysis of diaphragm or skeletal muscles
 - Decreased Total lung capacity (FVC)
 - Decreased FEV1 and FVC
 - Normal FEV1 /FVC




Taken from Spirometry quick reference guide. National Asthma Council Australia available at https://d8z57tiamduo7.cloudfront.net/resources/NAC_Spirometry-Quick-Reference-Guide_2020.pdf

Spirometry – obstructive defect with

reversibility

- Perform baseline spirometry
- Administer bronchodilator (4 puffs salbutamol via MDI and spacer
- Wait 10-15 minutes
- Repeat spirometry
- The obstructive defect is reversible because at least one of the two measurements (FVC or FEV₁) increased by at least 0.2 L and by at least 12%.

Figure taken from Johnson, J. and Theurer, W. A stepwise approach to the interpretation of pulmonary function tests. American Family Physician. 2014 Mar 1;89(5):359-366.



- A = FVC (before bronchodilators), this is > LLN and thus does not show a restrictive pattern
- $B = FEV_1$ (before bronchodilators)
- $C = FEV_1/FVC$ ratio (before bronchodilators), this is < LLN and thus shows an obstructive defect
- D = FVC percentage of predicted (before bronchodilators)
- $E = FEV_1$ percentage of predicted (before bronchodilators)
- F = FVC (after bronchodilators)

 $G = FEV_1$ (after bronchodilators)

H = FEV,/FVC ratio (after bronchodilators)

I = A 0.88-L increase in FVC is a 16% increase


J = A 1.09-L increase in FEV, is a 30% increase

The above indicates reversibility because at least one of the two (FVC or FEV₁) increased by at least 0.2 L and by at least 12%

Example respiratory report

- Things to note
 - Low baseline FEV1
 - Low baseline FEV1/FVC
 - Post-bronchodilator
 - Improvement in FEV1
 - Improvement in FVC
 - FEV1/FVC ration improvement

Figure 5 taken from: Borg, B. & Maughton, M. Spirometry. Australian Family Physician. 2011, April;40:4;216-219.



Peak flow meters


- Measures peak (maximum) rate at which a person can expel air
- Provides an indication of the degree of obstruction in
 - Asthma
 - COPD
- Only used by a minority of patient
 - Can objectively identify disease flares
 - Disease progress over time (spirometry better for this)
- Not diagnostic for asthma or COPD
- Just useful for home measurement



es/

PEAK EXPIRATORY FLOW RATE - NORMAL VALUES

For use with EU/EN13826 scale PEF meters only



Adapted by Clement Clarke for use with EN13826 / EU scale peak flow meters from Nunn AJ Gregg I, Br Med J 1989:298;1068-70

In men, readings up to 100 L/min lower than predicted are within normal limits. For women, the equivalent figure is 85 L/min. Values are derived from Caucasian populations.

Mini-Wright (Standard Range) EU scale (EN 13826)

Blue text on a yellow background



Single Patient Use Part Ref: 3103388

Multiple Patient Use Part Ref: 3103387

NHS Logistics Code: FDD 609

Mini-Wright (Low Range) EU scale

Blue text on a yellow background



Single Patient Use Part Ref: 3104708

Multiple Patient Use Part Ref: 3104710

Clement Clarke has developed mathematical equations that will allow conversion of P.E.F. readings from Wright-McKerrow scale to EN 13826 scale, and vice-versa. Contact us directly, or visit the website

www.peakflow.com





Precision by Tradition


Clement Clarke International Ltd. Edinburgh Way, Harlow, Essex. England CM20 2TT U.K.

Tel. +44 (0) 1279 414969 Fax. +44 (0) 1279 456304 www.clement-clarke.com email: resp@clement-clarke.com

(Issue 1 Date of preparation: 23rd July 2004)







Other Medications ...

©Woolcock Institute of Medical Research: